Monopar Therapeutics MNPR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$3.89M+25.1% | -$5.2M-51.3% | -$3.44M-40.1% | -$2.45M+6.5% | -$2.62M+76.0% | ||
| $1.69M+53.3% | $1.1M+0.4% | $1.1M-14.1% | $1.28M-5.6% | $1.36M+386% | ||
| -$3.47M-3.1% | -$3.37M-61.2% | -$2.09M-94.0% | -$1.08M+81.0% | -$5.66M-183% | ||
| -$5.58M+91.0% | -$62.19M-2,825% | -$2.13M-279% | $1.19M+464% | -$325.83K+97.7% | ||
| -$200.2K— | $0-100% | $92.39M+29,260% | -$316.85K-174% | -$115.68K-100% | ||
| -$9.29M— | —— | $88.18M+42,194% | -$209.47K+96.6% | -$6.1M-115% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Monopar Therapeutics generate?
- Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
- Where does Monopar Therapeutics's cash flow data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.